Nancy Stuart Sells 31,418 Shares of Concert Pharmaceuticals Inc (CNCE) Stock
Concert Pharmaceuticals Inc (NASDAQ:CNCE) COO Nancy Stuart sold 31,418 shares of the firm’s stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $17.87, for a total transaction of $561,439.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
CNCE traded down $0.40 during trading hours on Wednesday, reaching $17.26. 98,382 shares of the stock traded hands, compared to its average volume of 293,644. The firm has a market cap of $418.32 million, a price-to-earnings ratio of 4.27 and a beta of 1.09. Concert Pharmaceuticals Inc has a fifty-two week low of $12.87 and a fifty-two week high of $30.71.
Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.39. The business had revenue of $10.48 million during the quarter. Concert Pharmaceuticals had a net margin of 67.71% and a negative return on equity of 23.57%. analysts forecast that Concert Pharmaceuticals Inc will post -2.21 earnings per share for the current year.
A number of equities research analysts recently weighed in on CNCE shares. Mizuho reaffirmed a “buy” rating and set a $27.00 price target on shares of Concert Pharmaceuticals in a report on Tuesday, April 10th. ValuEngine raised shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, April 3rd. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Tuesday, May 1st. BidaskClub lowered shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 28th. Finally, HC Wainwright raised their price target on shares of Concert Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a report on Friday, May 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Concert Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $26.80.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.